David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to ...

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

A California-based biotech company announced it will be cutting roughly half of its workforce after a disappointing study result saw its stock plummet. Gossamer Bio confirmed to KRON4.com that it ...

Kraig Biocraft Laboratories (OTCQB:KBLB) deployed one million genetically engineered silkworm eggs across multiple ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...